GSK

GSK is expanding its AI-driven drug discovery efforts through a significant collaboration with Relation Therapeutics. This partnership leverages Relation’s expertise in generating high-volume, sophisticated human cell datasets. These datasets will train advanced AI models, including Relation’s MORGAN platform, to rapidly pinpoint novel drug targets. Building on prior successful collaborations, this agreement integrates cutting-edge data generation with AI model development for more precise therapeutic discovery.

Hengrui Pharma and GSK will co-develop up to 12 innovative medicines in a strategic partnership. GSK gains an exclusive license (excluding specific regions of China) for HRS-9821, a potential best-in-class PDE3/4 inhibitor for COPD, adding to their respiratory portfolio. Hengrui will advance 11 additional programs through Phase I, after which GSK can license them, paying $500M upfront. Hengrui could receive up to $12B in milestone payments and tiered royalties.